Zymeworks Launches $125M Share Repurchase Program
VANCOUVER, British Columbia, May 14, 2026 Zymeworks Inc. announced that its Board of Directors has approved a new 2026...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology oncology innovation Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
VANCOUVER, British Columbia, May 14, 2026 Zymeworks Inc. announced that its Board of Directors has approved a new 2026...
VALENCIA, Calif., May 14, 2026 SetPoint Medical announced the publication of a peer-reviewed health economics study demonstrating that its...
BOSTON, Feb. 2, 2026 — Red Nucleus, a global strategic partner to pharmaceutical and biotechnology companies, announced a definitive...
San Diego, California, January 21, 2026 — Artiva Biotherapeutics, a clinical-stage biopharmaceutical company focused on allogeneic natural killer (AlloNK)...
